Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference
There is no excerpt because this is a protected post.
Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond
TORONTO, ONTARIO June 24, 2022 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Investment Conference from June 27 – 28, 2022 in New York. Braxia Scientific CEO Dr. Roger McIntyre will deliver two live presentations at the conference beginning with a Keynote address - Introduction to the State of Mental Healthcare – to kick off the conference on Monday, June 27 at 8:15 a.m. ET Dr. McIntyre, will also deliver a second presentation on Monday, June 27 at 4:00 p.m. ET providing an overview of the Braxia’s business, including its progress on increasing access to novel ketamine and psychedelic treatments for patients with depression, while also expanding the...
WEBCAST ALERT: H.C. WAINWRIGHT VIRTUAL CONFERENCE PRESENTATION WEBCAST ALERT Dr. Roger McIntyre @ H.C. Wainwright Virtual Conference Presentation The Patient Experience and Commercial Considerations When Launching Psychoactive Agents in Psychiatry Tune in Live on Thursday, 6/17 at 2:00 PM (Eastern Standard Time) Webcast link is closed. Symbols – CSE: BRAX OTC: BRAXF FWB: 496